A total of 420 patients who underwent coronary arteriography due to suspected symptoms of CHD were enrolled, in which 220 were diagnosed as CHD and 200 were set as control subjects.
LncRNA THRIL in plasma samples of CHD patients and control subjects was detected by reverse transcription-quantitative polymerase chain reaction. Gensini score and biochemical indexes were evaluated in CHD patients and control subjects. Plasma inflammatory
cytokines were detected, and major adverse cardiovascular events (
MACE) were recorded in CHD patients.
RESULTS: Both before and after adjustment by age/gender,
lncRNA THRIL was increased in CHD patients compared with control subjects (both P < .001), and it well predicted enhanced CHD risk by receiver operating characteristic curves. For
coronary artery stenosis, it was positively correlated with Gensini score (P < .001, r = .430). For clinical characteristics,
lncRNA THRIL was positively correlated with
diabetes mellitus occurrence (P < .001) and fasting
blood glucose (FBG) level (P = .029, r = .147). For
inflammation, it was positively associated with CRP (P < .001, r = .374), TNF-α (P < .001, r = .249), IL-1β (P = .001, r = .222),
IL-8 (P < .001, r = .254), and
IL-17 (P = .011, r = .172), while negatively correlated with
IL-10 (P < .001, r = -.244). For prognosis,
lncRNA THRIL was positively associated with
MACE accumulating rate (P = .037) in CHD patients.
CONCLUSION: